Analytical Method Development for Endocannabinoid Biomarkers
Robust diagnostic interpretation depends on reliable measurement. Before endocannabinoid biomarkers can support any clinical or translational framework, the analytical procedures used to quantify them must be rigorously developed, validated, and maintained under real-world conditions.
Role of Mass Spectrometry in Endocannabinoid Quantification
Endocannabinoid biomarkers are present in human plasma at low endogenous concentrations, requiring analytical techniques capable of high sensitivity and specificity. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) is used to separate and quantify lipid signaling molecules in complex biological matrices.
This approach enables the detection of physiologically relevant concentrations while minimizing interference from structurally similar compounds and background noise. Analytical performance is evaluated based on sensitivity, specificity, reproducibility, and stability across a variable set of sample conditions, ensuring that measured values reflect true biological concentrations rather than artifacts of the analytical process.
Method Development as an Ongoing Process
Analytical methods validated under controlled conditions do not necessarily retain performance over time or across study environments. Variability introduced through sample collection, processing timelines, storage conditions, and matrix effects can alter measured concentrations without producing obvious indicators of failure.
Endocannabinoid signaling molecules are particularly sensitive to pre-analytical and analytical variables, including enzymatic degradation and lipid instability. As a result, method development in this context extends beyond initial validation and continues throughout the study’s lifecycle. Performance must be monitored and maintained under the same conditions under which data are generated, rather than assumed based on prior validation alone.
